Abstract:DNA damage repair (DDR) genes are involved in developing breast cancer. Recently, a targeted therapeutic strategy through DNA repair machinery, including PARPi, has initially shown broad development and application prospects in breast cancer therapy. However, few studies that focused on the correlation between the expression level of DNA repair genes, prognosis, and immune response in breast cancer patients have been recently conducted. Herein, we focused on identifying differentially expressed DNA repair genes (DEGs) in breast cancer specimens and normal samples using the Wilcoxon rank-sum test. Biofunction enrichment analysis was performed with DEGs using the R software "cluster Profiler" package. DNA repair genes were involved in multivariate and univariate Cox regression analyses. After the optimization by AIC value, 11 DNA repair genes were sorted as prognostic DNA repair genes for breast cancer patients to calculate risk scores. Simultaneously, a nomogram was used to represent the prognostic model, which was validated using a calibration curve and C-index. Single-sample gene set enrichment analysis (ssGSEA), CIBERSORT algorithms, and ESTIMATE scores were applied to evaluate the immune filtration of tumor samples. Subsequently, anticarcinogen sensitivity analysis was performed using the R software "pRRophetic" package. Unsupervised clustering was used to excavate the correlation between the expression level of prognostic-significant DNA repair genes and clinical features. In summary, 56 DEGs were sorted, and their potential enriched biofunction pathways were revealed. In total, 11 DNA repair genes (UBE2A, RBBP8, RAD50 , FAAP20, RPA3, ENDOV, DDB2, UBE2V2, MRE11 , RRM2B, and PARP3 ) were preserved as prognostic genes to estimate risk score, which was applied to establish the prognostic model and stratified breast cancer patients into two groups with high or low risk. The calibration curve and C-index indicated that they reliably predicted the survival of breast cancer patients. Immune filtration analysis, anticarcinogen sensitivity analysis, and unsupervised clustering were applied to reveal the character of DNA repair genes between low- and high-risk groups. We identified 11 prognosis-significant DNA repair genes to establish prediction models and immune responses in breast cancer patients.

DNA damage response in breast cancer and its significant role in guiding novel precise therapies

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

Targeting DNA damage response deficiency in the treatment of breast cancer

Advancing cancer therapy: new frontiers in targeting DNA damage response

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

DNA Damage Response Inhibitors: an Avenue for TNBC Treatment

Targeting DNA damage response pathways in cancer

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Targeting the DNA damage response in hematological malignancies

Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity

Construction of a DNA Damage Repair Gene Signature for Predicting Prognosis and Immune Response in Breast Cancer.

DNA damage repair and cancer immunotherapy

Advances of DNA Damage Repair-Related Drugs and Combination with Immunotherapy in Tumor Treatment

Enhancing the Anti-Tumor Response by Combining DNA Damage Repair Inhibitors in the Treatment of Solid Tumors

Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy

Role of DNA Repair Defects in Predicting Immunotherapy Response

Abstract IA017: Drugging the DNA damage response (DDR) in the Clinic: Going beyond the approved PARP inhibitors

Abstract MS1-3: Targeting DNA damage response and HRD in breast cancer